Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
about
Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?Management of cirrhotic ascitesHyponatremia and Hepatorenal SyndromeReview article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction.Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes.Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers.Low-dose tolvaptan for the treatment of dilutional hyponatremia in cirrhosis: a case report and literature review.Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia.Novel treatment options for portal hypertension.Prevention of the Osmotic Demyelination Syndrome After Liver Transplantation: A Multidisciplinary Perspective.Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach.Ascites, refractory ascites and hyponatremia in cirrhosis.Efficacy of peritoneovenous shunt for treating tolvaptan-resistant refractory ascites in a cirrhotic patient with portal vein thrombosis: A case report.Hyponatraemia and cirrhosis.Management of hyponatremia in clinical hepatology practice.Hyponatremia management in critically ill: Food (protein) for thought.Terlipressin and hyponatraemia: the cause or the treatment?The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis.Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.[Hyponatremia and tolvaptan : what is the situation 5 years after approval?].Correction of Hyponatremia May Be a Treatment Stratification Biomarker: A Two-Stage Systematic Review and Meta-Analysis
P2860
Q26778032-70F1388C-CB55-40A2-8CA0-66DA874CFD20Q34475601-4D0AE255-EF83-4B8F-A895-AA67ADBCF039Q36812531-D66E74B8-4C05-4401-A1FE-1FE92FD30E63Q38188048-7A6D7F05-BFAB-4F99-A820-F4DF7C07132CQ38199770-F00063AA-44F2-40CA-B06C-F05DF9764EB3Q38254071-9DDDC567-2E14-44BB-A8F1-050BA510681DQ38266482-0905CD46-B88D-4C59-BC2D-55F7E87F970DQ38325703-2B67E6CF-59F3-4F13-B356-1E58B9F8D696Q38680437-C6609B6A-94D4-4485-A7BA-7CE3441C9179Q39250455-902212B3-3BA9-42F4-AE2D-CF20C36CD5B2Q39304722-0990CEA3-703D-43F3-A6C7-CD5018F8DE6FQ39323841-B5E7179E-FD7A-4B8B-B5D9-70910458DBEBQ40496089-32C45867-6DC0-46D7-914D-DE1A719830D5Q41946824-0CAA33BD-3835-417E-A91F-BDC9436AE204Q42222640-309E77B2-20BD-42AC-B5A0-F0F91B6CD1A5Q43195038-B35E99B0-F5E5-444C-B052-8D20557321ABQ45795579-198EF47A-2CE8-40C1-8A0F-4B0C57499CFBQ47104649-B442BB9C-25AE-495B-9896-E28712C5EA92Q47139485-06F8C067-09CC-4218-8242-4B7930A5FEFBQ51816090-031BBAC5-6868-48A6-9FBB-816F1E058F48Q53510182-7F6C8DD4-76E6-4E11-9FE3-2F3959946E91Q58758423-78E02D44-F7FC-4C19-AD8D-38857B0BA33B
P2860
Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Meta-analysis: the safety and ...... with ascites or hyponatraemia.
@en
type
label
Meta-analysis: the safety and ...... with ascites or hyponatraemia.
@en
prefLabel
Meta-analysis: the safety and ...... with ascites or hyponatraemia.
@en
P2093
P2860
P356
P1476
Meta-analysis: the safety and ...... with ascites or hyponatraemia.
@en
P2093
P2860
P304
P356
10.1111/APT.12025
P407
P577
2012-08-21T00:00:00Z